HAE Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.…
Industry Peers
Medical DevicesKey Statistics
About Haemonetics (NYSE: HAE)
›
Haemonetics (NYSE: HAE) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 3,009 employees.
The shares were at 120.37 USD on 19 November 2026, up 63.8% over 52 weeks. Its 52-week range is 51.00 USD to 132.00 USD: the price is 8.8% below the high and 136.0% above the low.
At a market capitalisation of 5.48B USD, it trades at 53.3 times trailing earnings and 19.2 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 108% for HAE.
Haemonetics reports return on equity of 12.2%, an operating margin of 18.8% and revenue up 9.3% year over year.
Its debt exceeds its cash by 860.85M USD, a debt-to-equity ratio of 1.54. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 147.18 USD is 22.3% above the current price. The next earnings report is expected on 4 February 2027.